These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32684074)

  • 41. A New Era in the Treatment of Thyroid Eye Disease.
    Patel A; Yang H; Douglas RS
    Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease.
    Shams PN; Ma R; Pickles T; Rootman J; Dolman PJ
    Am J Ophthalmol; 2014 Jun; 157(6):1299-305. PubMed ID: 24582992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapies for thyroid eye disease.
    Kahaly GJ
    Curr Opin Endocrinol Diabetes Obes; 2019 Oct; 26(5):250-255. PubMed ID: 31356255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiotherapy for Active Thyroid Eye Disease.
    Godfrey KJ; Kazim M
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S98-S104. PubMed ID: 29771752
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Grading Severity and Activity in Thyroid Eye Disease.
    Dolman PJ
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S34-S40. PubMed ID: 29952931
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit.
    Mellington FE; Dayan CM; Dickinson AJ; Hickey JL; MacEwen CJ; McLaren J; Perros P; Rose GE; Uddin J; Vaidya B; Foley P; Lazarus JH; Mitchell A; Ezra DG;
    Orbit; 2017 Jun; 36(3):159-169. PubMed ID: 28296512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Minimally invasive surgery for thyroid eye disease.
    Naik MN; Nair AG; Gupta A; Kamal S
    Indian J Ophthalmol; 2015 Nov; 63(11):847-53. PubMed ID: 26669337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
    Krassas GE
    Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Teprotumumab for Thyroid-Associated Ophthalmopathy.
    Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
    N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of intravenous methylprednisolone immunosuppression in the management of active thyroid eye disease.
    Tambe K; Bhargava J; Tripathi A; Gregory M; Burns J; Sampath R
    Orbit; 2010 Oct; 29(5):227-31. PubMed ID: 20812826
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroid eye disease: Redefining its management-A review.
    Jain AP; Jaru-Ampornpan P; Douglas RS
    Clin Exp Ophthalmol; 2021 Mar; 49(2):203-211. PubMed ID: 33484076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.
    Ma Z; Ozaki H; Ishikawa Y; Jingu K
    Jpn J Radiol; 2019 Aug; 37(8):612-618. PubMed ID: 31201593
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phenotypes of Thyroid Eye Disease.
    Uddin JM; Rubinstein T; Hamed-Azzam S
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S28-S33. PubMed ID: 29905636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Graves’ orbitopathy in pediatrics].
    Mendoza F C; Lacourt R P
    Rev Med Chil; 2015 Aug; 143(8):1034-41. PubMed ID: 26436933
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low dose orbital radiotherapy for thyroid eye disease.
    Li Yim JF; Sandinha T; Kerr JM; Ritchie D; Kemp EG
    Orbit; 2011 Dec; 30(6):269-74. PubMed ID: 22132844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
    Hoang TD; Nguyen NT; Chou E; Shakir MK
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug safety in thyroid eye disease - a systematic review.
    Wolf J; Mitka KI; Hubalewska-Dydejczyk A; Krämer I; Kahaly GJ
    Expert Opin Drug Saf; 2022 Jul; 21(7):881-912. PubMed ID: 35447047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy.
    Alkawas AA; Hussein AM; Shahien EA
    Clin Exp Ophthalmol; 2010 Oct; 38(7):692-7. PubMed ID: 20497432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.